Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

  • STATUS
    Recruiting
  • End date
    Oct 30, 2022
  • participants needed
    115
  • sponsor
    Fudan University
Updated on 27 January 2021
cancer
tyrosine
filgrastim
measurable disease
carcinoma
metastasis
neutrophil count
differentiated thyroid cancer
thyrotropin
medullary thyroid carcinoma
thyroid carcinoma
follicular thyroid carcinoma
iodine uptake
iodine therapy
radioactive iodine therapy
anaplastic thyroid carcinoma

Summary

The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid cancer.

Description

We will recruit four types of advanced thyroid cancer patients. Arm A will enroll the radioactive Iodine-refractory differentiated thyroid cancer(RAIR-DTC). Arm B will recruit the advanced medullary thyroid cancer(MTC). Arm C will include the advanced anaplastic thyroid cancer(ATC). Arm D will include the differentiated thyroid cancer that unsuitable for 131I treatment.

This clinical trial will be conducted under Simon's optimal two-stage design.

For arm A, the first stage needs 8 participants, if 4 or more participants acquire remission, the study will move on to the second stage and enroll another 16 patients to achieve a total number of 24 participants enrolled.

For arm B, the first stage needs 8 participants, if 4 or more participants acquire remission, the study will move on to the second stage and enroll another 16 patients to achieve a total number of 24 participants enrolled.

For arm C, the first stage needs 13 participants, if 4 or more participants acquire remission, the study will move on to the second stage and enroll another 30 patients to achieve a total number of 43 participants enrolled.

For arm D, the first stage needs 8 participants, if 4 or more participants acquire remission, the study will move on to the second stage and enroll another 16 patients to achieve a total number of 24 participants enrolled.

Details
Condition Thyroid Adenoma, head and neck cancer, Thyroid disorder, Thyroid Disease, Thyroid Disorders, Thyroid Cancer, thyroid carcinoma
Treatment multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Clinical Study IdentifierNCT04521348
SponsorFudan University
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Thyroid Adenoma or Thyroid Cancer or Thyroid disorder or Thyroid Disorders or head and neck cancer or Thyroid Disease?
Do you have any of these conditions: thyroid carcinoma or Thyroid Cancer or Thyroid Disorders or head and neck cancer or Thyroid disorder or Thyroid Adenoma or Thyroid Disease?
Do you have any of these conditions: thyroid carcinoma or Thyroid Adenoma or head and neck cancer or Thyroid Cancer or Thyroid Disorders or Thyroid disorder or Thyroid Disease?
Do you have any of these conditions: Thyroid Adenoma or Thyroid Disease or head and neck cancer or Thyroid Cancer or Thyroid disorder or Thyroid Disorders or thyroid carcinoma?
Patients volunteered to participate in this study and signed informed consent
Age: 18 years old, male or female
Advanced thyroid cancer patients couldn't be treated by local treatment such as surgery or microwave ablation, and are confirmed by histopathology or cytology to be one of the following three types of thyroid cancer
Local advanced or metastatic differentiated thyroid cancer, including papillary thyroid carcinoma (including follicular subtypes and poorly differentiated subtypes) and thyroid follicular carcinoma (including Hrthle cell subtypes, etc.)
Local advanced or metastatic medullary thyroid carcinoma
Anaplastic thyroid cancer
Differentiated thyroid cancer patients need to meet the definition of radioiodine refractory or is not suitable for 131I treatment. The definition of radioactive iodine refractory is as follows (meet one of the following conditions)
At least one measurable lesion completely loses iodine uptake during radioiodine therapy
Although the lesion has iodine-receiving ability, at least one measurable lesion can still achieve progressive disease within 12 months after iodine131 treatment
has received a total dose of radioactive iodine therapy 22.2 GBq ( 600 mCi), and the final radioactive iodine therapy was within six months before enrollment
If the subject is a patient with differentiated thyroid cancer, the TSH level should be at the inhibition level (<0.5 micro unit/L) from the screening period
At least one measurable lesion (according to RECIST v1.1, long diameter of measurable lesion scanned by spiral CT should be 10 mm or short diameter of swollen lymph node should be 15 mm; according to RECIST vl.1 standards, a previously treated lesion with local treatment can be used as target lesions after clear progress)
Perfomance Status: 0~2
Estimated survival time 12 weeks
The main organs function are normal, and meet the following requirements (within 7 days before the start of study treatment)
Blood routine examination(no blood transfusion within 14 days before screening, no granulocyte colony stimulating factor (G-CSF), no medication corrected):1) Hemoglobin (HB) 90g / L;2) Neutrophil count (ANC) 1.5 109 / L;3) platelets (PLT) 80 109 / L
Blood biochemical tests are subject to the following criteria (no albumin is delivered 14 days prior to screening):1) Serum total bilirubin (BIL) 1.5 times the upper limit of normal (ULN); 2) alanine aminotransferase (ALT), aspartate aminotransferase (AST])< 2.5 ULN; if liver metastasis, ALT and AST 5 ULN;3) Serum creatinine (Cr) 1 ULN or endogenous creatinine clearance > 50ml / min (Cockcroft-Gault formula)
International normalized ratio (INR) 2.3 or prothrombin time (PT) exceeds the range of normal controls 6 seconds
Urine protein <2+ (if urine protein 2+, 24-hour urine protein can be quantified, 24-hour urine protein quantitation <1.0g can be included)
Women of childbearing age must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and volunteer to use appropriate methods during the observation period and within 8 weeks after the last study drug administration; for men, sterilization surgery should be performed, or agree to use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug
Patients voluntarily undergo tumor biopsy at the time of enrollment and out of the group
Patient who are expected to have good compliance and can accept follow-up visit for the efficacy and adverse reactions according to the program requirements

Exclusion Criteria

Have other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast carcinoma in situ, can be enrolled
Other anti-tumor treatments (including but not limited to chemotherapy, radiotherapy, etc.) were used within 28 days prior to the first use of the study drug. Except for thyroid stimulating hormone (TSH) inhibition therapy
Patients who have previously been treated with immunological checkpoint inhibitors (including but not limited to Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, etc.)
There are clinical symptoms or diseases of the heart that are not well controlled, such as
According to the New York Heart Association (NYHA) standard, level II or higher cardiac dysfunction or echocardiography: left ventricular ejection fraction<50%
unstable angina
Myocardial infarction occurred within 1 year before the start of treatment
Clinically significant supraventricular or ventricular arrhythmia that requires treatment or intervention
corrected QT interval(QTc) > 450ms (male); QTc > 470ms (female) (Calculation of QTc interval with Fridericia formula; if the QTc is abnormal, it can be detected three times at an interval of 2 minutes, and the average value is taken)
Patients with high blood pressure who cannot be reduced to normal range by antihypertensive medication (systolic blood pressure 140mmHg or diastolic blood pressure 90mmHg) (average of BP based on 2 measurements), allowing the use of antihypertensive treatment to achieve the above parameters; there have been hypertensive crisis or hypertensive encephalopathy previously
A variety of factors that affect the absorption of oral medications (such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction)
Patients with a risk of gastrointestinal bleeding may not be enrolled, including the following: (1) active digestive ulcer lesions, and fecal occult blood (++); (2) those with a history of melena and hematemesis within 3 months
Abnormal coagulation function (INR>1.5ULN,activated partial thromboplastin time>1.5ULN), with bleeding tendency
There is obvious hemoptysis within 2 months before screening, or hemoptysis volume is no less than half a teaspoon (2.5ml) per day
Imaging studies have shown that the tumor has invaded important blood vessels or that the patient's tumor has a high probability of invading important blood vessels during treatment and causing fatal bleeding
Thrombosis or embolic events occurred within 6 months prior to the start of treatment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc
Currently associated with interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring hormonal therapy, or other pulmonary fibrosis that may interfere with the assessment and management of immune-related pulmonary toxicity, Organized pneumonia (eg, bronchiolitis obliterans), pneumoconiosis, drug-associated pneumonia, idiopathic pneumonia, or evidence of active pneumonia or severe impaired lung function on a chest computed tomography (CT) scan during screening, but radiation pneumonitis is allowed in field of radiation: active tuberculosis
There is autoimmune disease or a history of active autoimmune disease which may recur (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis); patients who have skin diseases that do not require systemic treatment such as vitiligo, psoriasis, hair loss, patients who have controlled type 1 diabetes by using insulin, and patients who have completely relieved asthma in childhood and needn't intervention after be adults can be included; Asthmatic patients need bronchodilators for medical intervention cannot be included
Use immunosuppressive agents or systemic hormonal therapy for immunosuppression within 14 days prior to initiation of study treatment (dose > 10 mg/day of prednisone or other therapeutic hormones)
Use strong CYP3A4/CYP2C19 inducers including rifampicin (and its analogs) and hyperforin perforatum or strong CYP3A4/CYP2C19 inhibitors within 14 days prior to initiation of study treatment
Have a severe allergic history of any monoclonal antibody, anti-angiogenic targeted drug
Uncontrolled infections during screening
Pregnant or lactating women
Patients refused to undergo a biopsy of the tumor at the time of enrollment and out of the group
Other patients evaluated by physician to be unfit for inclusion
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note